Xeloda clinical trials
Xeloda is named as an intervention in 54 current clinical trials in our China, South Korea, USA, Spain, Germany, France, Italy, Canada, UK, Mexico, Japan, Israel, Brazil, Taiwan, Australia, Poland, Belgium, Turkey, Netherlands, Sweden, Switzerland, Czechia, Portugal, Singapore, Ireland, Austria, Denmark, Norway and India registers. 26 are recruiting patients now. The most common phase is Phase 2. The sponsor with the most trials is Merck Sharp & Dohme LLC (7). The most-studied condition is Breast Cancer.
Patient leaflets for Xeloda
The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.
- UKUnited Kingdom: Search MHRA ProductsPatient information leaflets and SmPCs for UK-licensed products.
- USUnited States: Search DailyMedFDA-approved labels, including patient and medication guides.
Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.
Trials by status
Trials by phase
Clinical trials of Xeloda
54 trialsRegisters list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Conditions studied with Xeloda
78 conditionsAll 78 conditions
| Condition (as registered) | Trials |
|---|---|
| Breast Cancer | 8 |
| Breast Neoplasms | 6 |
| Gastric Cancer | 4 |
| Triple Negative Breast Cancer | 3 |
| Esophageal Cancer | 3 |
| Rectal Cancer | 3 |
| HER2-negative Breast Cancer | 2 |
| Colonic Neoplasms | 2 |
| Neoadjuvant Therapy | 2 |
| Immune Checkpoint Inhibitors | 2 |
| Early Low Rectal Cancer | 2 |
| Triple-Negative Breast Cancer | 1 |
| Breast Cancer, Metastatic | 1 |
| Neoplasms | 1 |
| Locally Advanced or Unresectable Metastatic Breast Cancer | 1 |
| Stage IV Breast Cancer | 1 |
| Endometrial Cancer | 1 |
| Metastatic Castration-resistant Prostate Cancer | 1 |
| Ovarian Cancer | 1 |
| Solid Tumors | 1 |
| Triple Negative Breast Neoplasms | 1 |
| HR Low-Positive/HER2-Negative Breast Neoplasms | 1 |
| Metastatic Pancreatic Adenocarcinoma | 1 |
| Gastroesophageal Junction | 1 |
| Gastroesophageal Adenocarcinoma | 1 |
| Esophageal Neoplasms | 1 |
| Pancreatic Cancer | 1 |
| Colorectal Cancer (CRC) | 1 |
| Lung Cancer | 1 |
| Chemoradiotherapy | 1 |
| Rectal Cancer, Adenocarcinoma | 1 |
| Advanced Breast Cancer | 1 |
| Gastroesophageal Junction Adenocarcinoma | 1 |
| HER2-positive Gastric Cancer | 1 |
| Locally Advanced Rectal Cancer | 1 |
| Colorectal Cancer Metastatic | 1 |
| pMMR | 1 |
| MSS | 1 |
| MSI-L | 1 |
| Locally Advanced Rectal Carcinoma | 1 |
| Biliary Tract Cancer | 1 |
| Cholangiocarcinoma | 1 |
| Gallbladder Cancer | 1 |
| Refractory Breast Carcinoma | 1 |
| Gastric (Stomach) Cancer | 1 |
| Metastatic Breast Cancer | 1 |
| Gastric Adenocarcinoma | 1 |
| Esophageal Adenocarcinoma | 1 |
| Colon Adenocarcinoma | 1 |
| Stage IIA Colon Cancer AJCC v8 | 1 |
| Locally Advanced Unresectable Pancreatic Ductal Adenocarcinoma | 1 |
| Stage II Pancreatic Cancer AJCC v8 | 1 |
| Stage III Pancreatic Cancer AJCC v8 | 1 |
| Stage IV Pancreatic Cancer AJCC v8 | 1 |
| Anal Basaloid Carcinoma | 1 |
| Anal Canal Cloacogenic Carcinoma | 1 |
| Anal Canal Squamous Cell Carcinoma | 1 |
| Anal Margin Squamous Cell Carcinoma | 1 |
| Borderline Ovarian Mucinous Tumor | 1 |
| Ovarian Mucinous Cystadenocarcinoma | 1 |
| Recurrent Fallopian Tube Carcinoma | 1 |
| Recurrent Ovarian Carcinoma | 1 |
| Estrogen Receptor Negative | 1 |
| HER2/Neu Negative | 1 |
| Invasive Breast Carcinoma | 1 |
| Progesterone Receptor Negative | 1 |
| Metastatic Malignant Neoplasm in the Liver | 1 |
| Pancreatic Neuroendocrine Tumor | 1 |
| Stage I Pancreatic Neuroendocrine Tumor AJCC v8 | 1 |
| Stage II Pancreatic Neuroendocrine Tumor AJCC v8 | 1 |
| Gastric Neuroendocrine Carcinoma | 1 |
| Intestinal Neuroendocrine Carcinoma | 1 |
| Pancreatic Neuroendocrine Carcinoma | 1 |
| Colorectal Cancer | 1 |
| Stomach Neoplasms | 1 |
| Colorectal Neoplasms | 1 |
| Head and Neck Neoplasms | 1 |
| Gastro-Intestinal Intraepithelial Neoplasia | 1 |
Sponsors
lead sponsor per trial+ 16 more sponsors in the trial list above.
By country register
A trial with sites in more than one country appears in each of those registers.
Related compounds
Questions about Xeloda trials
How many clinical trials are testing Xeloda?
54 current trials in our China, South Korea, USA, Spain, Germany, France, Italy, Canada, UK, Mexico, Japan, Israel, Brazil, Taiwan, Australia, Poland, Belgium, Turkey, Netherlands, Sweden, Switzerland, Czechia, Portugal, Singapore, Ireland, Austria, Denmark, Norway and India registers name Xeloda (also registered as Sintilimab, oxalipaltin, 5FU,Nab-paclitaxel,lenvatinib) as a drug or biological intervention, as of the registry sync on 9 November 2026. Completed and withdrawn studies are not counted.
Are Xeloda trials recruiting patients?
Yes. 26 of the 54 trials are recruiting: 15 with sites in China, 11 with sites in South Korea, 10 with sites in USA, 9 with sites in Spain, 8 with sites in Germany, 9 with sites in France, 9 with sites in Italy, 8 with sites in Canada, 8 with sites in UK, 5 with sites in Mexico, 6 with sites in Japan, 7 with sites in Israel, 7 with sites in Brazil, 6 with sites in Taiwan, 6 with sites in Australia, 5 with sites in Poland, 4 with sites in Belgium, 6 with sites in Turkey, 3 with sites in Netherlands, 3 with sites in Sweden, 4 with sites in Switzerland, 4 with sites in Czechia, 4 with sites in Portugal, 4 with sites in Singapore, 3 with sites in Ireland, 1 with sites in Austria, 2 with sites in Denmark, 3 with sites in Norway and 2 with sites in India. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Who sponsors Xeloda clinical trials?
Merck Sharp & Dohme LLC (7), Sun Yat-sen University (4), Fudan University (4) and Gilead Sciences (3), among 31 lead sponsors in total. The number in brackets is how many trials each organisation leads.
Are there Xeloda clinical trials in Ireland?
Yes. 5 trials in our Ireland register (ClinicalTrials.gov). Some may be the same study registered in both. See the Irish clinical trials register for sites and contacts.
Where does this information come from?
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Xeloda works or whether it is effective, and it is not medical advice.
How this page is built
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Xeloda works or whether it is effective. Each trial links to its own record so you can check it yourself.
- ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Xeloda (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 9 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.